Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Apatinib for HCC Downstaging/Bridging
NCT04035876Phase 2Unknown
- Sponsor
- Zhejiang University
- Start
- Jul 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04035876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04035876.